Digest Network Come funziona
Network
/
Società
Cu
Non verificato

Curium

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute Benessere

16 comunicati stampa

Guarda tutti i comunicati
26/02/2026
Farmaceutica
Medicina Salute Benessere
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
03/02/2026
Farmaceutica
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
07/01/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
22/12/2025
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
20/11/2025
Farmaceutica
CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmaceutica
Management/Organizzazione Aziendale
Medicina Salute Benessere
Curium Announces First Commercial Doses of Diagnostic Radiopharmaceutical in Czech Republic and Slovakia for Patients with Prostate Cancer
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
17/11/2025
Farmaceutica
Annunci Economici
Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
14/10/2025
Farmaceutica
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
21/05/2025
Farmaceutica
Management/Organizzazione Aziendale
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0
12/05/2025
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Curium receives marketing authorization in Switzerland for PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
Fonte
Curium
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0